Management of Dyslipidemia in Adult Type 2 Diabetes Patients in India (SOLID)
This study has been completed.
Information provided by (Responsible Party):
First received: January 31, 2011
Last updated: February 20, 2013
Last verified: February 2013
The purpose of study to assess the control of dyslipidemia in the Indian diabetic population treated with any hypolipidemic agent.
Type 2 Diabetes Mellitus
||Observational Model: Cohort
Time Perspective: Cross-Sectional
||A Non Interventional, Cross Sectional, Epidemiological Study on the Management of Dyslipidemia in Type 2 DM Adult Patients in India
Primary Outcome Measures:
- Proportion of type 2 diabetic dyslipidemia patients achieving the target LDL goal according to ADA 2010. These patients should be on stable dose of Lipid Lowering Drugs(LDL) for at least 3 months [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
Secondary Outcome Measures:
- Proportion of dyslipidemia control rate according to american diabetes Association (ADA) 2010 criteria by age and gender [ Designated as safety issue: No ]
- Control of dyslipidemia by Lipid Lowering Drugs (LLDs) drugs alone or combination [ Designated as safety issue: No ]
- Control of dyslipidemia by all commercial available brands hypolipidemics drugs [ Designated as safety issue: No ]
Lipid profile ( Low Density Lipoproteins(LDL), High Density Lipoprotein (HDL), Triglycerides & Total cholesterol) Blood Glucose Measurements (Fasting Plasma Glucose)
| Study Start Date:
| Study Completion Date:
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Type 2 Diabetics with dyslipidemia on stable dose of Lipid Lowering Drugs(LLDs).
- Adult who is a known Type 2 diabetic as per the ADA 2010 criteria OR controlled diabetic (taking any antidiabetic medication)
- Patients in the study will have been on lipid lowering drugs at a stable dose for the last three months before the designated study visit.
- Type 1 diabetic patients
- Patients with a history of hepatic or renal diseases
- Hypertension due to organic diseases
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
No Contacts or Locations Provided
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||January 31, 2011
||February 20, 2013
||India: Drugs Controller General of India
Keywords provided by AstraZeneca:
Management of dyslipidemia in Type 2 Diabetes Mellitus adult patients in India
Dyslipidemia control rates in Type 2 diabetic Mellitus patients
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on July 26, 2014
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Endocrine System Diseases
Lipid Metabolism Disorders